Maze Therapeutics, Inc. Common Stock (MAZE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has a cash flow conversion efficiency ratio of -0.114x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.11 Million) by net assets ($341.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Maze Therapeutics, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Maze Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Maze Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinosteel Anhui Tianyuan Technology Co Ltd
SHE:002057
|
0.015x |
|
Guangdong Xinbao Electrical Appliances Holdings Co Ltd
SHE:002705
|
0.109x |
|
Guizhou Gas Group Corporation Ltd Class A
SHG:600903
|
-0.004x |
|
Allied Properties Real Estate Investment Trust
TO:AP-UN
|
0.001x |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
0.419x |
|
Malaysia Building Society Bhd
KLSE:1171
|
0.025x |
|
VGI Public Company Limited
BK:VGI-R
|
-0.002x |
|
Alphamin Res
V:AFM
|
0.124x |
Annual Cash Flow Conversion Efficiency for Maze Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Maze Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Maze Therapeutics, Inc. Common Stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $354.97 Million | $-111.94 Million | -0.315x | -181.75% |
| 2024-12-31 | $196.90 Million | $75.95 Million | 0.386x | +104.47% |
| 2023-12-31 | $10.05 Million | $-86.83 Million | -8.636x | -783.11% |
| 2022-12-31 | $101.44 Million | $-99.20 Million | -0.978x | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral s… Read more